Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1997 11
1998 12
1999 18
2000 20
2001 10
2002 8
2003 20
2004 22
2005 15
2006 18
2007 8
2008 15
2009 9
2010 11
2011 7
2012 11
2013 12
2014 9
2015 5
2016 9
2017 7
2018 5
2019 7
2020 12
2021 14
2022 18
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Lopez-Morinigo JD, Leucht S, Arango C. Lopez-Morinigo JD, et al. Pharmacopsychiatry. 2022 Sep;55(5):233-245. doi: 10.1055/a-1854-0185. Epub 2022 Jul 1. Pharmacopsychiatry. 2022. PMID: 35777418 Free PMC article. Review.
Early-onset schizophrenia (EOS) - onset before age 18 - is linked with great disease burden and disability. ...Treatment-resistant patients should be offered clozapine. Future long-term trials looking at cognition, functioning, quality of life, suicidal behav …
Early-onset schizophrenia (EOS) - onset before age 18 - is linked with great disease burden and disability. ...Treatment-re …
Current Evidences on Psychopharmacology of Schizoaffective Disorder.
Muñoz-Negro JE, Cuadrado L, Cervilla JA. Muñoz-Negro JE, et al. Actas Esp Psiquiatr. 2019 Sep;47(5):190-201. Epub 2019 Sep 1. Actas Esp Psiquiatr. 2019. PMID: 31648341 Free article. Review.
Apart from these difficulties, very few studies focused in SAD as a distinct condition from schizophrenia have been found. This lack of specifical studies on SAD results in a lack of specific evidence about treatment. ...In treatment-refractory patients, there are o …
Apart from these difficulties, very few studies focused in SAD as a distinct condition from schizophrenia have been found. This lack …
Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia.
Liu JL, Tan ZM, Jiao SJ. Liu JL, et al. World J Psychiatry. 2023 Jul 19;13(7):453-460. doi: 10.5498/wjp.v13.i7.453. eCollection 2023 Jul 19. World J Psychiatry. 2023. PMID: 37547736 Free PMC article.
BACKGROUND: Treatment-refractory schizophrenia (TRS), accounting for approximately 30% of all schizophrenia cases, has poor treatment response and prognosis despite treatment with antipsychotic drugs. AIM: To analyze the therapeutic effectiveness of repetitiv …
BACKGROUND: Treatment-refractory schizophrenia (TRS), accounting for approximately 30% of all schizophrenia cases, has …
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M. Chouinard G, et al. Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24. Psychother Psychosom. 2017. PMID: 28647739 Free article. Review.
We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and …
We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-ge …
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.
Faden J, Citrome L. Faden J, et al. Expert Opin Pharmacother. 2019 Jan;20(1):11-24. doi: 10.1080/14656566.2018.1543409. Epub 2018 Nov 8. Expert Opin Pharmacother. 2019. PMID: 30407873 Review.
Schizophrenia is a debilitating condition with three main symptom domains: positive, negative, and cognitive. Approximately one-third of persons with schizophrenia will fail to respond to treatment. Growing evidence suggests that treatment-resistant ( …
Schizophrenia is a debilitating condition with three main symptom domains: positive, negative, and cognitive. Approximately one-third …
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
Zahodne LB, Fernandez HH. Zahodne LB, et al. Drugs Aging. 2008;25(8):665-82. doi: 10.2165/00002512-200825080-00004. Drugs Aging. 2008. PMID: 18665659 Free PMC article. Review.
Preliminary reports have also shown a potential relationship between deep brain stimulation surgery and PD psychosis.When reduction in anti-PD medications to the lowest tolerated dose does not improve psychosis, further intervention may be warranted. Several atypical antipsychoti …
Preliminary reports have also shown a potential relationship between deep brain stimulation surgery and PD psychosis.When reduction in anti- …
What does the PANSS mean?
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. Leucht S, et al. Schizophr Res. 2005 Nov 15;79(2-3):231-8. doi: 10.1016/j.schres.2005.04.008. Epub 2005 Jun 27. Schizophr Res. 2005. PMID: 15982856 Clinical Trial.
METHOD: PANSS and CGI ratings at baseline (n = 4091), and after one, two, four and six weeks of treatment taken from a pooled database of seven pivotal, multi-center antipsychotic drug trials on olanzapine or amisulpride in patients with exacerbations of schizophrenia …
METHOD: PANSS and CGI ratings at baseline (n = 4091), and after one, two, four and six weeks of treatment taken from a pooled database of se …
Olanzapine for schizophrenia.
Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Duggan L, et al. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001359. doi: 10.1002/14651858.CD001359.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846619 Review.
There are very few data for people with first episode illness (1 RCT, duration 6 weeks, n=42). For people with treatment-resistant illness there were no clear differences between olanzapine and clozapine (4 RCTs, n=457). AUTHORS' CONCLUSIONS: The large propor …
There are very few data for people with first episode illness (1 RCT, duration 6 weeks, n=42). For people with treatment-resistant …
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review.
Gannon L, Reynolds J, Mahon M, Gaughran F, Lally J. Gannon L, et al. Ther Adv Psychopharmacol. 2023 May 11;13:20451253231168788. doi: 10.1177/20451253231168788. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37187727 Free PMC article. Review.
BACKGROUND: Treatment-resistant schizophrenia (TRS) affects approximately 30% of people with schizophrenia. ...Clozapine was superior to high-dose olanzapine in a double-blind crossover trial. Open-label studies demonstrated tentative evidence i …
BACKGROUND: Treatment-resistant schizophrenia (TRS) affects approximately 30% of people with schizophrenia. ...C …
A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia.
Dong S, Schneider-Thoma J, Bighelli I, Siafis S, Wang D, Burschinski A, Schestag K, Samara M, Leucht S. Dong S, et al. Eur Arch Psychiatry Clin Neurosci. 2023 Aug 1. doi: 10.1007/s00406-023-01654-2. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 37526675
We aimed to examine the efficacy and adverse events of different antipsychotics in treatment-resistant schizophrenia by performing a network meta-analysis. ...CONCLUSIONS: Clozapine remains the gold standard for patients with treatment-resistant …
We aimed to examine the efficacy and adverse events of different antipsychotics in treatment-resistant schizophrenia by …
307 results